Dupilumab reduces exacerbations in COPD with type 2 inflammation
1. In this randomized controlled trial, patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation who received dupilumab ...
Tag: dupilumab
#VisualAbstract: Dupilumab Improves Outcomes in COPD with Blood Eosinophil Evidence of Type 2 Inflammation
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Dupilumab reduces the number exacerbations in patients with COPD and type two inflammation
1. In this randomized controlled trial, dupilumab use was associated with significantly fewer chronic obstructive pulmonary disease (COPD) exacerbations among ...
Dupilumab For Management of Bullous Pemphigoids
1. Dupilumab treatment for bullous pemphigoids resulted in improved clinical symptoms. 2. Patients with anti-BP180 antibody levels of at least ...
#VisualAbstract: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Dupilumab improves symptoms and increases remission rates in eosinophilic esophagitis
1. Weekly dupilumab resulted in a significantly increased rate of histologic remission as compared to placebo in patients with eosinophilic ...
Dupilumab plus topical corticosteroids are effective in the treatment of childhood atopic dermatitis
1. By week 16, 28% of patients in dupilumab reported clear or almost clear skin (IGA 0-1) compared to 4% ...
Abrocitinib is more effective than dupilumab for treatment of moderate-to-severe atopic dermatitis
1. The co-primary endpoints at weeks 2 and 4 were significantly greater with abrocitinib than dupilumab. 2. Overall incidence of ...
Dupilumab reduces systemic glucocorticoid use in severe asthmatics
1. Glucocorticoid dependent severe asthmatics treated with dupilumab for 24 weeks used significantly lower doses of glucocorticoids while maintaining asthmatic ...